Department of Ophthalmology, CHU de Grenoble, University Hospital, University Joseph Fourier, 38043, Grenoble Cedex 09, France.
Graefes Arch Clin Exp Ophthalmol. 2012 Sep;250(9):1367-71. doi: 10.1007/s00417-012-1926-7. Epub 2012 Jan 25.
To report the safety and efficacy of 23-gauge (23-G) transconjunctival vitrectomy (TSV) in the surgical management of postoperative endophthalmitis.
Ten consecutive patients underwent a 23-G TSV in 2008-2010 after cataract surgery (n = 5) or filtrating surgery (n = 5), and were prospectively studied with a minimum follow-up of 6 months. TSV was performed within a median delay of 1 day after the diagnosis, after one or two injections of intravitreal antibiotics (vancomycin, ceftazidime). Conventional cultures (brain heart infusion media) and/or panbacterial PCR were performed on aqueous humor and/or vitreous samples.
Initial visual acuity was less than or equal to hand motion in all cases, and clinical findings included hypopyon (80%), pupillary fibrin membrane (80%), and dense vitreitis (4+, 100%). The bacteria identified were Gram-positive cocci in 60% of the cases (coagulase-negative staphylococci, 20%; streptococcus, 40%) and Gram-negative bacilli in 10% (moraxella lacunata). All patients had central and peripheral vitrectomy (mean duration, 58.6 ± 16 min). No intraoperative complications were noted. Two patients developed retinal detachment postoperatively and were reoperated. The final visual vision was 20/400 for two patients and 20/50 or better for the other patients.
23-G TSV allows the surgeon to meet the same objectives as the 20-G technique for the treatment of endophthalmitis.
报告 23 号(23-G)经结膜玻璃体切除术(TSV)在治疗术后眼内炎中的安全性和疗效。
2008 年至 2010 年,10 例连续患者在白内障手术(n = 5)或滤过性手术(n = 5)后接受了 23-G TSV,且进行了至少 6 个月的前瞻性研究。TSV 在诊断后 1 天内进行,在玻璃体腔内注射 1 或 2 次抗生素(万古霉素、头孢他啶)后进行。对房水和/或玻璃体样本进行常规培养(脑心浸液培养基)和/或全细菌 PCR。
所有病例初始视力均≤手动,临床发现包括前房积脓(80%)、瞳孔纤维蛋白膜(80%)和浓密玻璃体炎(4+,100%)。鉴定的细菌中,60%为革兰阳性球菌(凝固酶阴性葡萄球菌,20%;链球菌,40%),10%为革兰阴性杆菌(莫拉菌属)。所有患者均进行了中央和周边玻璃体切除术(平均持续时间 58.6 ± 16 分钟)。术中未发现并发症。2 例患者术后发生视网膜脱离并再次手术。最终视力为 2 例患者 20/400,其余患者 20/50 或更好。
23-G TSV 允许外科医生达到与 20-G 技术相同的治疗眼内炎的目标。